作者
Jean De Gunzburg, Amine Ghozlane, Annie Ducher, Emmanuelle Le Chatelier, Xavier Duval, Etienne Ruppé, Laurence Armand-Lefevre, Frédérique Sablier-Gallis, Charles Burdet, Loubna Alavoine, Elisabeth Chachaty, Violaine Augustin, Marina Varastet, Florence Levenez, Sean Kennedy, Nicolas Pons, France Mentré, Antoine Andremont
发表日期
2018/1/30
期刊
The Journal of infectious diseases
卷号
217
期号
4
页码范围
628-636
出版商
Oxford University Press
简介
Background
Antibiotics are life-saving drugs but severely affect the gut microbiome with short-term consequences including diarrhea and selection of antibiotic-resistant bacteria. Long-term links to allergy and obesity are also suggested. We devised a product, DAV132, and previously showed its ability to deliver a powerful adsorbent, activated charcoal, in the late ileum of human volunteers.
Methods
We performed a randomized controlled trial in 28 human volunteers treated with a 5-day clinical regimen of the fluoroquinolone antibiotic moxifloxacin in 2 parallel groups, with or without DAV132 coadministration. Two control goups of 8 volunteers each receiving DAV132 alone, or a nonactive substitute, were added.
Results
The coadministration of DAV132 decreased free moxifloxacin fecal concentrations by 99%, while plasmatic levels were unaffected …
学术搜索中的文章
J De Gunzburg, A Ghozlane, A Ducher, E Le Chatelier… - The Journal of infectious diseases, 2018